Latest Neurotech Pharmaceuticals Inc. Stories
LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP).
CUMBERLAND, R.I., Oct.
LINCOLN, R.I., Sept. 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today that the U.S.